Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform

Xenetic Biosciences, Inc.

2023-Q3 EPS reported -$1.94 revenue$1,868,023

Net loss of $1.1M for Q3 2023; cash at $9.8M.
R&D expenses rose 155.9% to $1.0M on DNase platform preclinical work.
Royalty income from Takeda sublicense up 47.5% to $0.6M.
Advancing DNase platform toward first-in-human study for pancreatic carcinoma.
G&A expenses down 14.6% to $0.7M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Xenetic Biosciences, Inc. reported financial results for the three months ended September 30, 2023.

Period: the three months ended September 30, 2023
Result: reported results

Exact text from the filing

On November 10, 2023, Xenetic Biosciences, Inc. (the “Company”) issued a press release announcing results for the three months ended September 30, 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-007922

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.